Neo Scientific — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Neo Scientific is a private, revenue-generating biotechnology services company focused on providing essential research tools, including custom peptides, antibodies, and immunoassays, to the global scientific community. Leveraging its Cambridge location, the company combines traditional biochemical services with emerging AI-driven design capabilities for proteins and antigens. Its business model is primarily service-based, catering to academic, pharmaceutical, and diagnostic research labs, with a clear expansion strategy into technology-enabled product development. While currently in a commercial stage for its services, its foray into AI-designed biomolecules positions it for potential platform growth.

DiagnosticsAI / Machine Learning

Technology Platform

Combines traditional biochemical services (peptide synthesis, antibody production) with AI/ML for protein and antigen design, and offers an ELISA Builder tool for custom assay development.

Opportunities

Leveraging AI to design superior antigens and proteins could create a high-margin, differentiated service line and open partnerships in diagnostics and drug discovery.

Expanding GMP peptide services addresses the growing preclinical and clinical development market, offering significant value to emerging biotech companies.

Risk Factors

Faces intense competition from large, established players and low-cost providers in the research tools market.

The AI/ML initiative carries execution risk, requiring significant expertise and data to deliver reliable, valuable designs that customers will pay a premium for.

Competitive Landscape

Competes in the crowded life sciences research tools and services market against giants like Thermo Fisher Scientific and GenScript, as well as many niche specialists. Differentiation is currently based on turnaround time and breadth of catalog, but the planned AI design platform could position it against newer computational biology startups if successfully implemented.

More companies in Small Molecule Drugs →More companies in United States →